Understanding how glucose transport varies in lung adenocarcinoma
Official title: Investigating the heterogeneity of glucose transport in lung adenocarcinoma
Funded at University of California Los Angeles · NIH-11013894 · Data updated 2026-11-12
This study is looking at how a specific sugar transporter in your body affects lung cancer, especially in its early stages, to help us understand how the disease grows and find better ways to treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | February 1, 2020 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $479,934 |
| NIH project number | 5R01CA237401-06 |
| Project ID | NIH-11013894 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early-stage lung adenocarcinoma.
✕Less likely to help
Patients with advanced lung cancer who do not express SGLT2 may not benefit from this research.
What this research studies
This research investigates the role of glucose transport in lung adenocarcinoma, a common type of lung cancer. It focuses on the sodium-glucose transporter 2 (SGLT2) and its involvement in early-stage tumors, as well as how the expression of glucose transporters changes as the cancer progresses. By using advanced imaging techniques like positron emission tomography (PET), the study aims to explore the differences in glucose metabolism between early and advanced stages of the disease. This could lead to new insights into how lung cancer develops and progresses, potentially informing future treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for lung adenocarcinoma patients.
How similar studies have gone: Previous research has shown promising results in targeting glucose metabolism in cancer, suggesting potential for success in this approach.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Scafoglio, Claudio — University of California Los Angeles
- Study coordinator: Scafoglio, Claudio
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.